Last reviewed · How we verify

CorMedix — Portfolio Competitive Intelligence Brief

CorMedix (CRMD) pipeline: 1 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

CRMD (NASDAQ) 1 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Taurolidine and Heparin Taurolidine and Heparin marketed Anti-coagulant [EPC]
Neutrolin Neutrolin phase 3 Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. American University of Beirut Medical Center · 1 shared drug class
  3. ApoPharma · 1 shared drug class
  4. Azienda Ospedaliera V. Cervello · 1 shared drug class
  5. Consorzio per Valutazioni Biologiche e Farmacologiche · 1 shared drug class
  6. Hikma Pharm Co Ltd · 1 shared drug class
  7. Novartis · 1 shared drug class
  8. The George Institute · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CorMedix:

Cite this brief

Drug Landscape (2026). CorMedix — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cormedix. Accessed 2026-05-15.

Related